List of Excipients in Branded Drug PANTOPRAZOLE SODIUM DR
Generic Drugs Containing PANTOPRAZOLE SODIUM DR
What are the Most Frequently-Used Excipients in PANTOPRAZOLE SODIUM DR?
| # Of NDCs | Excipient |
|---|---|
| 1 | AMMONIA |
| 1 | CALCIUM STEARATE |
| 1 | CARNAUBA WAX |
| 1 | FERRIC OXIDE YELLOW |
| 1 | FERROSOFERRIC OXIDE |
| 1 | HYDROXYPROPYL CELLULOSE |
| 1 | HYPROMELLOSES |
| ># Of NDCs | >Excipient |
Pantoprazole Sodium Delayed-Release Excipient Strategy and Commercial Opportunities
Pantoprazole sodium delayed-release products are mature, genericized proton-pump inhibitors with limited opportunity for composition-of-matter exclusivity. Commercial differentiation is concentrated in excipient selection, enteric-coating performance, stability, supply reliability, dosage-form convenience, and regulatory execution. The strongest opportunities are low-cost, robust delayed-release tablets; sprinkle or suspension products for patients who cannot swallow tablets; and specialized excipient systems that improve moisture control, coating efficiency, and bioequivalence performance.
What is pantoprazole sodium delayed release?
Pantoprazole sodium is the sodium salt of pantoprazole, a substituted benzimidazole proton-pump inhibitor. It suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase after activation in the acidic secretory canaliculi of gastric parietal cells (U.S. Food and Drug Administration [FDA], 2023).
The “DR” designation means delayed release. The dosage form is designed to protect pantoprazole from degradation in the stomach and release the drug in the more alkaline environment of the small intestine.
| Attribute | Pantoprazole sodium delayed-release product |
|---|---|
| Active ingredient | Pantoprazole sodium sesquihydrate or equivalent salt form |
| Therapeutic class | Proton-pump inhibitor |
| Common strengths | 20 mg and 40 mg pantoprazole equivalent |
| Primary oral form | Enteric-coated delayed-release tablet |
| Other forms | Delayed-release granules, oral suspension products, intravenous formulation |
| Reference product | Protonix delayed-release tablets |
| Main release site | Small intestine |
| Main formulation challenge | Protection from gastric acid and moisture-induced degradation |
| Regulatory pathway for generics | Abbreviated New Drug Application, typically with therapeutic-equivalence requirements |
Pantoprazole sodium delayed-release tablets are different from immediate-release acid-suppression products. The formulation must maintain chemical integrity through gastric transit and deliver the active ingredient after intestinal release.
What excipients are used in pantoprazole sodium delayed-release tablets?
Pantoprazole delayed-release tablets generally use a tablet core, a protective subcoat, and an enteric coating. Exact compositions vary by manufacturer and are disclosed in product labeling, regulatory filings, or technical documentation.
Typical excipient architecture
| Formulation layer | Typical excipient functions | Common excipient classes |
|---|---|---|
| Tablet core | Dilution, binding, disintegration, lubrication | Mannitol, microcrystalline cellulose, povidone, crospovidone, croscarmellose sodium, calcium stearate, magnesium stearate |
| Drug-protective subcoat | Separates pantoprazole from acidic or reactive coating components | Hypromellose, polyvinyl alcohol, polyethylene glycol, talc |
| Enteric coat | Resists gastric fluid and dissolves at intestinal pH | Methacrylic acid copolymers, hypromellose phthalate, hypromellose acetate succinate |
| Film-coating additives | Plasticization, pigment, opacity, processing | Polyethylene glycol, propylene glycol, titanium dioxide, talc, iron oxides |
| Packaging system | Moisture and light protection | High-barrier blister, aluminum-aluminum blister, desiccant bottle |
The original Protonix delayed-release tablet formulation includes mannitol, crospovidone, povidone, calcium stearate, hypromellose, titanium dioxide, talc, propylene glycol, and an enteric polymer system, according to product labeling (FDA, 2023).
A generic manufacturer does not need to duplicate the brand’s excipient formula. It must demonstrate pharmaceutical equivalence and bioequivalence while meeting quality, stability, dissolution, and manufacturing requirements.
Which excipients are most important for pantoprazole stability?
Pantoprazole is sensitive to acidic conditions and can degrade during processing or storage if the formulation does not provide adequate protection.
Alkaline microenvironment
An alkaline or neutral microenvironment can reduce acid-catalyzed degradation. Excipients that influence microenvironmental pH may be important, especially in multiparticulate or suspension formulations.
Manufacturers must control:
- Residual acidic impurities
- Water activity
- Coating polymer acidity
- API-excipient compatibility
- Granulation moisture
- Compression heat and dwell time
- Storage humidity
- Migration of coating components into the drug layer
The formulation should not expose pantoprazole directly to acidic enteric polymers. A protective subcoat is often used to isolate the drug-containing core from the enteric layer.
Moisture control
Moisture can affect both chemical stability and enteric-coating performance. Commercial options include:
- Low-moisture excipients
- Controlled-humidity manufacturing
- High-barrier packaging
- Aluminum-aluminum blister systems
- Desiccant-containing bottles
- Moisture-scavenging secondary packaging
- Reduced aqueous exposure during coating
A lower-cost bottle configuration may be commercially attractive, but it must be supported by accelerated and long-term stability data. Moisture protection is often a greater commercial differentiator than the choice between two functionally similar binders.
Binder and disintegrant selection
Povidone can provide binding capacity but may influence moisture uptake. Crospovidone supports rapid tablet breakup after enteric-coat dissolution. Croscarmellose sodium provides a similar disintegration function but can produce different swelling and dissolution behavior.
The preferred combination depends on:
- Drug loading
- Tablet hardness
- Compression force
- Coating weight gain
- Disintegration time after enteric release
- Dissolution profile across multiple pH stages
- Scale-up behavior
What formulations are protected by pantoprazole patents?
The original patent estate covered pantoprazole and related pharmaceutical compositions. Those core rights have expired in the United States, and pantoprazole sodium is widely available from generic manufacturers.
Later patents and regulatory exclusivities may have addressed:
- Delayed-release dosage forms
- Enteric-coated tablets
- Granule and pellet systems
- Oral suspensions
- Intravenous formulations
- Specific treatment methods
- Manufacturing processes
- Salt forms or solid-state characteristics
- Combination therapies
The commercial relevance of any later patent depends on claim scope, jurisdiction, expiration, terminal disclaimers, patent-term adjustment, and whether the patent is listed in the FDA Orange Book.
What is the Orange Book status of pantoprazole sodium delayed release?
Pantoprazole sodium delayed-release tablets are a mature generic market. The FDA Orange Book identifies reference-listed drugs and therapeutically equivalent generic products, including multiple abbreviated new drug applications for common strengths and dosage forms (FDA, 2024).
| Regulatory issue | Commercial position |
|---|---|
| Reference product | Protonix delayed-release tablets |
| Generic pathway | ANDA |
| Typical dosage strengths | 20 mg and 40 mg |
| Market maturity | High |
| Composition-of-matter exclusivity | Expired |
| Biosimilar pathway | Not applicable |
| Main approval risks | Bioequivalence, dissolution, stability, impurity control, manufacturing consistency |
| Current competitive lever | Cost, supply reliability, dosage-form differentiation, contracting |
Orange Book status must be reviewed by product, strength, dosage form, and patent listing. A manufacturer should not assume that the absence of an active patent listing eliminates all litigation risk, because unlisted process, manufacturing, trade-secret, or foreign rights can remain relevant.
When did pantoprazole lose exclusivity?
Pantoprazole’s principal U.S. exclusivity period ended years ago, and generic products entered the market in the 2000s. Protonix faced substantial generic-entry pressure after settlements and litigation involving generic manufacturers. The product is now commercially mature, with competition based primarily on manufacturing economics and distribution access rather than basic patent exclusivity.
The key timing distinction is between:
- Regulatory exclusivity for the reference product.
- Listed Orange Book patents.
- Unlisted formulation or process patents.
- Foreign patent rights.
- Market-entry settlements involving individual generic applicants.
For current U.S. entrants, the central question is not whether the original pantoprazole molecule remains protected. It does not. The question is whether a proposed formulation creates a new, enforceable patent position or avoids third-party rights.
How strong is the patent estate for pantoprazole sodium delayed release?
The patent estate is weak for conventional 20-mg and 40-mg delayed-release tablets. Basic pantoprazole protection has expired, and numerous generic products demonstrate that the core product can be manufactured without relying on a single protected formulation.
Patent strength is higher only where a product has a genuinely differentiated technical feature, such as:
- A narrowly defined multiparticulate system
- A novel coating sequence
- A specific pH-triggered release profile
- A difficult-to-reproduce impurity-control process
- A pediatric suspension with validated stability
- A combination product with a separate therapeutic claim
- A manufacturing process that materially improves yield or purity
Even in these areas, patent value depends on claim breadth and enforceability. A patent covering only a narrow excipient ratio may have limited blocking power if competitors can use alternative polymers or coating levels.
What generic entry risks exist for pantoprazole delayed-release tablets?
Generic entry risk is high for standard tablets because:
- The molecule is mature.
- The reference product has extensive clinical and regulatory history.
- Generic manufacturing technology is established.
- Multiple excipient systems can achieve delayed release.
- API and enteric-polymer suppliers are widely available.
- The product does not require a biosimilar development program.
The main development risks are technical rather than patent-based.
Bioequivalence and dissolution risk
A generic product must match the reference product’s performance closely enough to satisfy FDA requirements. Critical tests include:
- Assay and content uniformity
- Acid-stage resistance
- Buffer-stage dissolution
- Impurity profile
- Stability under ICH conditions
- In vitro release consistency
- Pharmacokinetic bioequivalence, where required
Enteric coating thickness, polymer grade, plasticizer level, and curing conditions can materially change dissolution. A product that passes initial release testing may fail after storage if the coating becomes brittle, tacky, or permeable.
Manufacturing risk
Manufacturing risks include:
- Uneven coating weight
- Tablet edge chipping
- Delamination
- Core porosity variation
- Inadequate subcoat coverage
- API segregation
- Moisture uptake
- Raw-material variability
- Long coating-cycle times
A formulation with a narrow process window may be technically patentable but commercially unattractive if it lowers throughput or increases batch failure rates.
Which companies compete in pantoprazole sodium delayed release?
The market includes the reference-product sponsor and multiple generic manufacturers. U.S. product availability varies by strength, dosage form, wholesaler, and supply period.
Common generic-market participants have included:
- Viatris and legacy Mylan operations
- Teva Pharmaceutical Industries
- Dr. Reddy’s Laboratories
- Zydus Pharmaceuticals
- Lupin
- Sun Pharmaceutical Industries
- Amneal Pharmaceuticals
- Apotex
- Endo and legacy Par Pharmaceutical operations
- Hikma and other regional suppliers
The competitive landscape changes as manufacturers discontinue products, transfer ANDAs, or adjust supply based on contract pricing. FDA’s Drugs@FDA and Orange Book databases are the primary sources for current approval and therapeutic-equivalence status (FDA, 2024).
What commercial opportunities exist in pantoprazole excipients?
The largest opportunity is not a new active ingredient. It is a lower-cost and more reliable product platform.
Low-cost conventional tablets
A manufacturer can compete through:
- Direct compression or simplified granulation
- High-throughput aqueous or organic coating
- Reduced coating weight
- Common excipient sourcing
- Standardized 20-mg and 40-mg tablet tooling
- High-barrier but cost-controlled packaging
The product must preserve acid resistance and dissolution while minimizing processing time.
Sprinkle and oral suspension products
Patients with dysphagia, feeding tubes, or pediatric needs may require products other than conventional tablets. Multiparticulate formulations can use:
- Drug-layered inert pellets
- Enteric-coated granules
- Suspending agents
- Wetting agents
- Osmotic or viscosity modifiers
- Single-dose sachets
- Ready-to-use oral suspension vehicles
This segment has higher formulation complexity and can support stronger differentiation. It also creates higher stability and administration risks, particularly after reconstitution.
Excipient supply opportunities
Excipient suppliers can target:
- Enteric polymers with consistent acid resistance
- Low-moisture binders
- High-functionality mannitol
- Co-processed filler-disintegrant systems
- Film-coating premixes
- Plasticizer systems with lower migration
- Barrier coatings
- Moisture-control packaging
A supplier with regulatory support, global documentation, and reliable lot-to-lot performance can capture value even in a price-sensitive generic market.
Manufacturing and licensing opportunities
Licensing opportunities are most credible where a platform solves a measurable problem:
- Lower coating time
- Better stability in bottles
- Lower impurity formation
- Improved suspension shelf life
- Reduced tablet size
- Greater compatibility with continuous manufacturing
- Improved feeding-tube administration
- Reduced dependence on a constrained excipient
A generic product license may include an ANDA, manufacturing site, formulation package, drug-master-file access, or regional distribution rights. The economic value depends heavily on approved manufacturing capacity and customer contracts.
How does pantoprazole compare with omeprazole and esomeprazole?
Pantoprazole competes with other proton-pump inhibitors, especially omeprazole, esomeprazole, lansoprazole, and rabeprazole.
| Factor | Pantoprazole | Omeprazole | Esomeprazole |
|---|---|---|---|
| Market maturity | Mature generic | Mature generic | Mature generic with branded legacy |
| Typical oral technology | Enteric-coated tablet or granule | Enteric-coated capsule, tablet, or granule | Enteric-coated tablet or capsule |
| Excipient challenge | Acid protection and moisture control | Acid protection and multiparticulate consistency | Similar delayed-release requirements |
| Patent leverage | Low for standard products | Low for standard products | Higher historical product-line complexity |
| Commercial differentiation | Cost, supply, suspension, IV/oral portfolio | Volume and broad dosage-form range | Brand positioning and specialty formulations |
| Biosimilar risk | None | None | None |
Pantoprazole can be attractive when a manufacturer wants a mature proton-pump inhibitor with established demand and relatively predictable technical requirements. It is less attractive as a standalone product if the company lacks scale, distribution, or a differentiated dosage form.
What patent litigation and Paragraph IV risks remain?
For standard pantoprazole sodium delayed-release tablets, Paragraph IV risk is generally limited because the principal patents have expired and the market has multiple generic suppliers. New Paragraph IV activity would most likely involve:
- A newly listed formulation patent
- A pediatric or suspension dosage form
- A combination product
- A new strength or release profile
- A manufacturing or solid-state patent
- A later-developed branded product
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The commercial impact depends on the patent’s listing date, the first filer’s eligibility for 180-day exclusivity, litigation timing, and settlement terms under the Hatch-Waxman framework.
What are the geographic opportunities for pantoprazole excipients and products?
The United States is a mature generic market with significant price pressure. Europe, Canada, Latin America, India, Southeast Asia, and selected Middle Eastern markets can offer opportunities where:
- Local generic penetration remains fragmented
- Tender systems reward reliable supply
- Regional manufacturing reduces logistics costs
- Local registration of excipients is established
- Hospitals use intravenous and oral pantoprazole
- Pediatric or dysphagia-friendly forms are underdeveloped
Geographic patent risk must be assessed separately. U.S. expiry does not establish freedom to operate in Europe, Japan, China, India, or other jurisdictions. Local formulation patents, regulatory data rules, compulsory licensing regimes, and manufacturing-site requirements can change the economics.
What is the FDA regulatory status of pantoprazole sodium delayed release?
Pantoprazole delayed-release tablets are FDA-approved prescription products, and generic versions are approved through the ANDA pathway. The regulatory focus is pharmaceutical equivalence, bioequivalence, manufacturing controls, impurity limits, dissolution, and stability.
The product is not a biologic and does not require a biosimilar application. FDA approval does not grant protection for a particular excipient composition unless the formulation is separately patented and enforceable.
Key Takeaways
- Pantoprazole sodium delayed-release tablets are mature, genericized products with high generic-entry risk.
- The main technical challenge is protecting pantoprazole from acid and moisture.
- A robust formulation normally separates the drug core from the acidic enteric coating with a protective subcoat.
- Mannitol, povidone, crospovidone, hypromellose, talc, titanium dioxide, plasticizers, and methacrylic acid copolymers are representative excipient components.
- Standard tablet patent strength is low because the principal molecule and early formulation protections have expired.
- Commercial value is concentrated in manufacturing efficiency, packaging, supply reliability, and differentiated oral dosage forms.
- Sprinkle, granule, suspension, pediatric, and feeding-tube products offer more defensible opportunities than another conventional 20-mg or 40-mg tablet.
- Biosimilar risk is not relevant because pantoprazole is a small-molecule drug.
- Current Orange Book, ANDA, patent, and therapeutic-equivalence status must be assessed product by product.
- Excipient suppliers can create value through enteric polymers, moisture-control systems, co-processed excipients, and regulatory support.
FAQs
Is pantoprazole sodium delayed release the same as pantoprazole immediate release?
No. Delayed-release pantoprazole is protected from gastric release and is designed to dissolve in the intestine. Immediate-release pantoprazole formulations use different technologies and may require buffering agents or other protective systems.
Can a company patent a new pantoprazole excipient combination?
Yes, if the combination is novel, non-obvious, adequately disclosed, and produces a defensible technical effect. A narrow excipient ratio without a demonstrated performance advantage may provide limited commercial protection.
Which packaging is best for pantoprazole delayed-release tablets?
High-barrier packaging is generally preferred where moisture sensitivity is material. Aluminum-aluminum blisters can provide strong protection, while bottles may reduce packaging cost if supported by stability data and suitable desiccant control.
Is pantoprazole suitable for pediatric formulation development?
Yes, but pediatric development is more technically demanding. A product may require small, enteric-coated granules, a stable suspension, acceptable taste, dosing flexibility, and compatibility with feeding tubes.
Does pantoprazole have biosimilar competition?
No. Pantoprazole is a small-molecule drug. Competition occurs through generic drug applications, not biosimilar applications.
References
-
U.S. Food and Drug Administration. (2023). Protonix (pantoprazole sodium) delayed-release tablets and intravenous injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.
-
International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products. ICH.
-
International Council for Harmonisation. (2005). Q8(R2): Pharmaceutical development. ICH.
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
Visit the Subscription Options page for details on plans and pricing.
ISSN: 2162-2639

Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Access the Complete Database
Deeper Knowledge, Faster
- Analyze global market entry opportunities
- Identify first generic entrants
- Uncover prior art in expired and abandoned patents